Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PPID | Q08752 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8035251 | 0.88 | MEN1 (0.50) | MEN1KMT2AAGTR1KDM4EALDH1A1 | |
| SCHEMBL9742572 | 0.86 | TSHR (0.61) | KMT2AKDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL5807040 | 0.86 | KDM4E (0.53) | MEN1KMT2AAGTR1KDM4EALDH1A1 | |
| SCHEMBL31518574 | 0.86 | KDM4E (0.58) | MEN1KMT2AAGTR1KDM4EALDH1A1 | |
| SCHEMBL8047673 | 0.86 | TSHR (0.51) | MEN1KMT2AAGTR1KDM4EALDH1A1 | |
| SCHEMBL19159810 | 0.86 | ALDH1A1 (0.48) | MEN1KMT2AAGTR1KDM4EALDH1A1 | |
| SCHEMBL8047226 | 0.86 | KMT2A (0.56) | MEN1KMT2AAGTR1KDM4EALDH1A1 | |
| SCHEMBL7528637 | 0.85 | KDM4E (0.71) | MEN1KMT2AKDM4EALDH1A1NPC1 | |
| SCHEMBL7301777 | 0.83 | TOP2A (0.53) | MEN1KMT2AKDM4EALDH1A1PKM | |
| SCHEMBL6607746 | 0.82 | ALDH1A1 (0.50) | MEN1KMT2AAGTR1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462620-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM, PLC (GB) | 2008-12-09 | — | — | US | disclosed |
| EP-1337517-B1 | PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2008-11-26 | — | — | EP | disclosed |
| US-7169924-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-01-30 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | ELLIOTT RICHARD L | 2006-10-26 | — | — | US | disclosed |
| EP-1657238-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-17 | — | — | EP | disclosed |
| US-20050245552-A1 | N-substituted pyridinone and pyrimidinone derivatives for use as lp-pla2 inhibitors in the treatment of artherosclerosis | GLAXO GROUP LIMITED (GB) | 2005-11-03 | — | — | US | disclosed |
| US-20050153964-A1 | Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| EP-1492787-A2 | (CONDENSED) PYRIMIDONE AND (CONDENSED) PYRIDONE COMPOUNDS, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2005-01-05 | — | — | EP | disclosed |
| EP-1492533-A1 | N-SUBSTITUTED PYRIDINONE AND PYRIMIDINONE DERIVATIVES FOR USE AS LP-PLA2 INHIBITORS IN THE TREATMENT OF ARTHEROSCLEROSIS | GLAXO GROUP LIMITED (GB) | 2005-01-05 | — | — | EP | disclosed |
| US-5780628-A | Process for producing dioxoquinazolines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-07-14 | — | — | US | disclosed |
| EP-0789020-A1 | Process for producing dioxoquinazolines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-08-13 | — | — | EP | disclosed |
| EP-0444924-B1 | Fused 7-membered cyclic compound and antipsychotic preparation containing the same | SUNTORY LTD (JP) | 1996-01-03 | — | — | EP | disclosed |
| US-5312625-A | Fused 7-membered cyclic compound and antipsychotic preparation containing the same | SUNTORY LIMITED (JP) | 1994-05-17 | — | — | US | disclosed |
| CN-1017242-B | NEW QUIANZOLINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION | FUJISAWA PHARMACEUTICAL CO (JP) | 1992-07-01 | — | — | CN | disclosed |
| EP-0444924-A1 | Fused 7-membered cyclic compound and antipsychotic preparation containing the same | SUNTORY LIMITED (JP) | 1991-09-04 | — | — | EP | disclosed |
| US-4883800-A | DIABETES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-11-28 | — | — | US | disclosed |
| US-4734419-A | Quinazoline derivatives, compositions thereof and their use in treating diabetic complications | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-03-29 | — | — | US | disclosed |
| CN-86106984-A | New quinazoline derivant and preparation method thereof | — | 1987-05-20 | — | — | CN | disclosed |
| EP-0218999-A2 | New quinazoline derivatives, process for their production and pharmaceutical compositions comprising them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | NR5A1, GNRHR, RXFP3 | MEN1 1223/4885KMT2A 1132/4885AGTR1 739/4885 |
| US-20050153964-A1 | Pyrimidone compounds which are inhibitors of the enzyme Lp-PLA2; use in treating atheroscelerosis | LYPLAL1, PLA2G12A, ENPP2 | MEN1 2539/4885KMT2A 2447/4885AGTR1 208/4885 |
| US-20050245552-A1 | N-substituted pyridinone and pyrimidinone derivatives for use as lp-pla2 inhibitors in the treatment of artherosclerosis | PLA2G12A, PLA2G4B, PLA2G1B | MEN1 2281/4885KMT2A 3388/4885AGTR1 352/4885 |
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | PLA2G7, PLA2G1B, PLA2G4B | MEN1 3656/4885KMT2A 2798/4885AGTR1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.